

**Bölüm 3.7.3****METASTATİK PROSTAT KANSERİNDE NÜKLEER TEDAVİ YÖNTEMLERİ**Mehtap Güler AVCI<sup>1</sup>Emrah BİROL<sup>2</sup>Meryem KAYA<sup>3</sup>**GİRİŞ**

Sağlık Bakanlığı halk sağlığı Türkiye kanser istatistikleri verilerine göre Türkiye’de 2013-2017 yılları arasında erkeklerde görülen kanserlerin yaşa göre standardize edilmiş hızları içinde prostat kanseri akciğer kanserlerinden sonra ikinci sırada gelmektedir. Kanser ölümlerinde ise 4. sırada yer almaktadır.

Prostat kanseri hastalarının önemli bir kısmı medikal veya cerrahi kastrasyon ile uygulanan hormonal tedaviye rağmen metastatik safhaya ilerlemekte ve hormonal tedaviye direnç göstermektedir. Kastrasyona dirençli metastatik prostat kanseri (KDMPK) hastalarının beklenen yaşam süresinin 9 ile 13 ay arasında olduğu gösterilmiştir (1).

Son yıllarda hormonal tedaviye eklenen kemoterapötik ve androjen deprivasyon ajanlarının hastaların sağkalımına katkı sağladığı bildirilmekle birlikte hastaların çoğunluğu tedaviye rağmen nüks etmekte ve/veya progrese olmaktadır.

Radyoligand tedavi, bir peptid ve şelatlanmış beta ışını yayan bir radyonüklidli oluşun spesifik radyofarmasötüğün, kanser hücrelerine sitotoksik radyasyon vermesi amacıyla intravenöz olarak sistemik uygulandığı bir işlemdir.

<sup>1</sup> Uzm. Dr., Başakşehir Çam ve Sakura Şehir Hastanesi, Nükleer Tıp Kliniği, drmehtapgulerr@gmail.com

<sup>2</sup> Uzm. Dr., Başakşehir Çam ve Sakura Şehir Hastanesi, Nükleer Tıp Kliniği, dr\_emrahbirol@hotmail.com

<sup>3</sup> Prof. Dr., Başakşehir Çam ve Sakura Şehir Hastanesi, Nükleer Tıp Kliniği, bmeryemkaya@yahoo.com

## KAYNAKLAR

1. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. *Int J Clin Pract* 2011;65(11):1180-92.
2. Mhawech-Fauceglia B, Zhang S, Terracciano L, et al. Prostate specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using multiplex immunofluorescence. *Histopathology* 2007;50:472-483.
3. Perner S, Hofer MD, Kim R, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. *Hum Pathol* 2007;38:696-701.
4. Heck MM, Retz M, D'Alessandria C, et al. Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. *J Urol*. 2016;196(2):382-391.
5. Heck MM, Tauber R, Schwaiger S, et al. Treatment Outcome, Toxicity, and Predictive Factor for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. *Eur Urol*. 2019;75(6):920-926.
6. Hennrich U, Eder M. [177Lu]Lu-PSMA-617 (Pluvicto™): The First FDA-Approved Radiotherapeutic for Treatment of Prostate Cancer. *Pharmaceuticals (Basel)*. 2022 Oct 20;15(10):1292.
7. NCCN Guidelines Version 1.2023 Prostate Cancer.
8. Hofman MS, Violet J, Hicks RJ, et al. [177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. *Lancet Oncol*. 2018;19(6):825-833.
9. Yadav MP, Ballal S, Bal C, et al. Efficacy and safety of 177Lu-PSMA-617 radioligand therapy in metastatic castration resistant prostate cancer patients. *Clin Nucl Med*. 2020;45(1):19-31.
10. Ahmadzadehfar H, Rahbar K, Baum RP, et al. Prior therapies as prognostic factors of overall survival in metastatic castration resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). *Eur J Nucl Med Mol Imaging*. 2021 Jan;48(1):113-122.
11. Ahmadzadehfar H, Matern R, Baum RP, et al. The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicenter study. *J Nucl Med*. 2021;48:4067-76.
12. Von Eyben FE, Singh A, Zhang J, et al. 177Lu-PSMA radioligand therapy of predominantly lymph node metastatic prostate cancer. *Oncotarget*. 2019;10(25):2451-2461.
13. Hofman MS, Emmett L, Sandhu S, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. *Lancet*. 2021;397(10276):797-804.
14. Barber TW, Singh A, Kulkarni HR, et al. Clinical outcomes of 177Lu-PSMA radioligand therapy in earlier and later phases of metastatic castration-resistant prostate cancer grouped by previous taxane chemotherapy. *J Nucl Med*. 2019 Jul;60(7):955-962.
15. Morris MJ, De Bono JS, Chi KN, et al. Phase 3 study of lutetium 177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). *J Clin Oncol*. 2021;39(suppl 15):LBA4- LBA4.
16. Prive BM, Peters SMB, Muselaers CHJ, et al. Lutetium-177-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer: a prospective pilot study. *Clin Cancer Res*. 2021 Jul 1;27(13):3595-3601.
17. Clinicaltrials.gov. An international prospective open-label, randomized, phase III study comparing 177Lu-PSMA-617 in combination with Soc, Versus SoCalone, in adult male patients with mHSPC—full text view—ClinicalTrials.gov. 2022.

18. Kratochwil C, Bruchertseifer F, Giesel FL, et al.  $^{225}\text{Ac}$ -PSMA-617 for PSMA-Targeted alpha-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. *J. Nucl. Med.* 2016, 57, 1941–1944.
19. Zacherl MJ, Gildehaus FJ, Mittlmeier L, et al. First Clinical Results for PSMA-Targeted alpha-Therapy Using  $(^{225}\text{Ac})\text{-PSMA-I\&T}$  in Advanced-mCRPC Patients. *J. Nucl. Med.* 2021, 62, 669–674.
20. Ballal S, Yadav MP, Sahoo RK, et al.  $^{225}\text{Ac}$ -PSMA-617-targeted alpha therapy for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis. *Prostate.* 2021 Jun;81(9):580-591.
21. Ma J, Li L, Liao T, et al. Efficacy and Safety of  $^{225}\text{Ac}$ -PSMA617-Targeted Alpha Therapy in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. *Front Oncol.* 2022 Feb 3;12:796657.
22. Van der Doelen MJ, Mehra N, Van Oort IM, et al. Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with  $^{225}\text{Ac}$ -PSMA-617 targeted alpha-radiation therapy. *Urol Oncol.* 2021 Oct;39(10):729.e7-729.e16.
23. Khreish F, Ebert N, Ries M, et al.  $(^{225}\text{Ac})\text{PSMA-617}/(^{177}\text{Lu})\text{-PSMA-617}$  tandem therapy of metastatic castration-resistant prostate cancer: Pilot experience. *Eur. J. Nucl. Med. Mol. Imaging* 2020, 47, 721–728.
24. Ahumada JV, Rueda SDG, Solis FAS, et al. Multitarget Molecular Imaging in Metastatic Castration-Resistant Adenocarcinoma Prostate Cancer with Therapy-Induced Neuroendocrine Differentiation. *Diagnostics* 2022, 12, 1387.
25. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, et al. Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. *N Engl J Med* 2013; 369(3):213-23.